53
Participants
Start Date
September 5, 2018
Primary Completion Date
January 7, 2025
Study Completion Date
June 16, 2025
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
MIV-818 - oral capsules; pembrolizumab - IV
MIV-818 (fostroxacitabine bralpamide) + lenvatinib
MIV-818 - oral capsules; lenvatinib - oral capsules
Antwerp University Hospital, Antwerp
University Hospitals Gasthuisberg, Leuven
Hospital General Universitario Gregorio Marañón, Madrid
CHA Bundang Medical Center, Gyeonggi-do
Pusan National University Hospital, Pusan
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Seoul
Hospital Clinic Carrer Rosselló 161, Barcelona
Hospital Vall Hebrón, Barcelona
START Barcelona HM Nou Delfos, Barcelona
Hospital Universitario 12 de Octubre, Madrid
START Madrid-FJD, Madrid
Beatson West of Scotland Cancer Care, Glasgow
Guy's Hospital, Oncology and Clinical Trials, London
Northern Institute for Cancer Research, Newcastle upon Tyne
Chruchill Hospital, Cancer and Haematology Centre, Oxford
Lead Sponsor
Medivir
INDUSTRY